Catheter-based, radiofrequency renal denervation is a cost-effective solution for patients with hypertension, according to a study published Aug. 13 in the Journal of the Society for Cardiovascular Angiography & Interventions.
David Kandzari, MD, from the Piedmont Heart Institute, led a group of researchers to assess the cost-effectiveness of renal denervation based on clinical event risk reduction, quality of life measures and projected lifetime costs. Data from the SPYRAL HTN-ON MED study was used for the assessment.
"The cost-effectiveness of [renal denervation] was robust across a broad range of scenarios and sensitivity analyses," the researchers wrote.
The study found that renal denervation had an incremental cost-effectiveness ratio of $32,732 per quality-adjusted life years. Ratios below $50,000 per quality-adjusted life years are considered to indicate an intervention is cost-effective and has "high value," according to an Aug. 23 TCTMD report.